Xofigo® (radium-223 dichloride): Important Safety Information Update Regarding Increased Incidence of Deaths and Fractures in a Randomized Clinical Trial with Xofigo® used in Combination with Abiraterone Acetate and Prednisolone/ Prednisone

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

Date: 8 December 2017

 

Description:

Preliminary data from a randomised clinical trial showed an increased incidence of fractures (24% vs. 7%) and deaths (27% vs. 20%) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (CRPC) receiving Xofigo® in combination with abiraterone acetate and prednisolone/ prednisone.

Further analysis of these results is being carried out, and the measures outlined below should be followed until more information is available:

  • Do not treat patients with metastatic CRPC with Xofigo® in combination with abiraterone acetate and prednisolone/ prednisone.
  • Continued monitoring for fractures should be considered for patient who were previously treated with Xofigo® in combination with abiraterone acetate and prednisolone/ prednisone.

     

A Direct Healthcare Professional Communication (DHPC) has been issued by Bayer Co. (Malaysia) Sdn. Bhd. in agreement with NPRA to highlight this safety issue. Please refer to this DHPC for further information.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA